



Cerebellar Transcranial Direct Current Stimulation (ctDCS) Ameliorates Phantom Limb Pain and Non-painful Phantom Limb Sensations

Tommaso Bocci^{1,2} · Giuliano De Carolis³ · Roberta Ferrucci² · Mery Paroli³ · Federica Mansani² · Alberto Priori² · Massimiliano Valeriani^{4,5} · Ferdinando Sartucci¹

Published online: 4 March 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

Phantom limb pain (PLP) is a disabling and intractable sensation arising in about 80% of patients after amputation. The aim of this study was to evaluate the possibility to modulate nociceptive processing and pain perception with cerebellar transcranial direct current stimulation (ctDCS) in patients suffering from painful and non-painful phantom limb sensations. Fourteen upper limb amputees underwent ctDCS (anodal or sham, 2.0 mA, 20 min per day, 5 days a week). Clinical scores and electrophysiological parameters were assessed before tDCS, at the end of the 5-day treatment, 2 and 4 weeks later. Laser-evoked potentials (LEPs) were obtained from the stump using a Nd:YAP laser by pulses with short duration (5 ms) and small diameter spots (5 mm). Changes in visual analogue scores (VAS) were evaluated (chronic pain, paroxysmal pain, stump pain, phantom movements, phantom sensations). Anodal polarization significantly dampened LEP amplitudes (N1, $p = 0.021$ and N2/P2, $p = 0.0034$), whereas sham intervention left them unchanged. Anodal ctDCS significantly reduced paroxysmal pain ($p < 0.0001$), non-painful phantom limb sensations ($p < 0.0001$) and phantom limb movements ($p = 0.0003$), whereas phantom limb and stump pain did not change compared to the sham condition. Anodal ctDCS significantly improves both paroxysmal pain and non-painful phantom limb sensations, which are likely induced by maladaptive changes in the sensorimotor network and posterior parietal cortex respectively.

Keywords Phantom limb pain · tDCS · Cerebellum · Cerebellar tDCS · Phantom pain treatment · Pain tDCS

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s12311-019-01020-w>) contains supplementary material, which is available to authorized users.

✉ Ferdinando Sartucci
ferdinando.sartucci@med.unipi.it

¹ Section of Neurophysiopathology, Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa 2, 20142 Pisa, Italy

² “Aldo Ravelli” Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan & ASST Santi Paolo e Carlo, Milan, Italy

³ Anesthesiology & Pain Therapy Unit, Santa Chiara University Hospital, Pisa, Italy

⁴ Division of Neurology, Ospedale Bambino Gesù, Rome, Italy

⁵ Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark

Introduction

Phantom limb pain (PLP) is an intractable and disabling sensation arising after amputation and occurring in about 80% of patients [1–3]. Ambroise Paré was the first to describe the phenomenon in 1554, suggesting that both peripheral factors and central pain memory might contribute [4]. The pain is referred to the distal portion of the amputated limb, as stabbing, throbbing, burning, or cramping, and it is commonly associated with non-painful phantom limb sensations.

Central factors seem to mainly contribute to its pathogenesis, both at a cortical and spinal level, comprising functional reorganization of cortical sensorimotor maps [5–8] and spinal “phenotypic switch” in the expression of neuropeptides [2, 9]. In particular, studies reported that the severity of pain and the degree of topographic reorganization are positively correlated, suggesting that maladaptive changes may be primed by nociceptive input before the amputation [10–13]. More recently,

the “maladaptive model” has been reviewed as some authors found a strong correlation between PLP severity and residual activity in the primary sensorimotor missing limb cortex [14, 15].

To date, PLP remains a challenge for clinicians and neuroscientists. The short- and long-term effectiveness of pharmacological interventions is still debated [1, 16]. Most of the studies were limited by their small sample sizes and different pharmacological effects on either painful or non-painful phenomena; also, invasive spinal cord stimulation (SCS) failed to demonstrate long-lasting effects, likely due to its poor somatotopic specificity [17, 18].

Recently, some studies have suggested that the cerebellum may exert a key role in the sensory-motor integration aimed at antinociceptive behavior [19] and in behavioral responses to nociceptive stimulation [20]. In papers from our laboratory, we have shown that cerebellar transcranial direct current stimulation (ctDCS) modulates pain perception in humans, probably by interfering with the inhibitory tone exerted by the cerebellum over cortical areas (cerebellar brain inhibition (CBI) [21, 22]); accordingly, in chronic pain syndromes, the modulation of CBI using non-invasive brain stimulation (NIBS) techniques seems to interfere with maladaptive motor patterns, improving pain and promoting motor skills acquisition [23]. Further support for the usefulness of ctDCS comes from a paper showing that anodal stimulation reduces lower extremity pain perception [24].

The aim of this study was to evaluate the effects of ctDCS on amputated patients with phantom limb pain and non-painful phantom limb sensations. Pain improvement was assessed by clinical scores and neurophysiological parameters (laser-evoked potentials (LEPs)). LEPs offer a unique opportunity to study the sensory-discriminative, as well as the affective-emotional dimension of pain, which are differently carried by medial and lateral spinal nociceptive systems and rely on the activation of distinct cortical areas [25, 26], whereas N1 refers to the activation of somatosensory areas, N2-P2 complex likely origins from a wide network, including caudal and rostral regions of the anterior cingulate cortex [27, 28].

Materials and Methods

Patients

Fourteen patients were recruited from the inpatient and outpatient population of the Pain Therapy Unit of the Cisanello Hospital in Pisa. All the patients suffered from unilateral upper limb amputation (eight left, six right). Table 1 reports a summary of the demographic and clinical data.

Inclusion criteria were as follows: (1) age 18 to 70 years; (2) normal score (> 24) at the Mini-Mental State Examination; (3) limb amputation at least 6 months before study enrolment;

(4) stable presence of PLP for at least 2 months, (5) no coexistence of major neurologic, neuropsychological, and psychiatric diseases; and (6) stable pharmacological therapy during the month before the inclusion.

The Groningen Questionnaire Problems after Amputation [3] was used to assess time, side, level, and reason of amputation; duration of pain experienced before amputation; frequency of phantom sensation, phantom pain, and stump pain; amount of trouble and suffering experienced as a consequence of these sensations; type of phantom sensations; medical treatment received for phantom pain and/or stump pain and self-medication (Table 1). The questionnaire was administered before the experimental procedure.

Experimental Protocol

In a crossover, double-blind, sham-controlled design, each patient underwent sham and anodal ctDCS. All patients carried out the two experimental conditions, held at least 3 months apart to avoid carry-over effects. Each session, either anodal or sham, lasted 5 days a week (Monday to Friday, 20 min a day).

Both the electrophysiological assessment and clinical scores were assessed at baseline (T_0), immediately at the end of the stimulation week (T_1), 2 weeks (T_2) and 4 weeks (T_3) later.

Patients were enrolled by a physician with expertise in pain medicine (G.D.C.); clinical scores were administered by a psychologist (F.M.), whereas electrophysiological recordings were performed by a neurologist (T.B.), both blinded to the ctDCS condition.

Informed consent was obtained from all individual participants included in the study. The study was approved by the local ethical committee at the University of Pisa (formally named “Comitato Etico di Area Vasta Nord Ovest della Toscana”), in accordance with the tenets of Helsinki.

Clinical Evaluation

Patients were asked to rate their pain state on a 10-cm VAS at baseline (T_0), immediately at the end of the ctDCS week (T_1), 2 weeks (T_2) and 4 weeks (T_3) later [29, 30]. VAS scores were used to assess (1) PLP intensity (i.e., pain felt constantly in the phantom limb: 0 = absent, 10 = the worst possible PLP); (2) pain paroxysms (i.e., episodes of increased PLP above the background level); (3) stump pain; (4) non-painful phantom limb sensation, including the “telescoping phenomenon” (0 = lack of phantom sensation, 10 = the most intense phantom sensation possible); and (5) phantom limb movements (0 = immobilized phantom limb, 10 = limb easily moved). The order of the VAS ratings was randomized across patients and each evaluation session.

Table 1 Demographic and clinical assessment

Patient's number	Age/sex	Etiology of amputation	Site of amputation	Months from amputation	Phantom sensations	PLP	Prosthesis/physical therapy	Timeline of intervention
1	29/F	Traumatic	L lower arm	19	Movement, hot or cold	Squeezing, pressure	Yes/No	Anodal/sham
2	35/F	Traumatic	L lower arm	23	Tingling, cold	Electric discharge, squeezing	No/No	Sham/anodal
3	38/M	Traumatic	L upper arm	9	Movement, cold, itching	Pressure, stabbing	No/No	Anodal/sham
4	42/F	Traumatic	R lower arm	11	Itching, tingling,	Electric discharge, stabbing, pressure	Yes/No	Sham/anodal
5	32/F	Traumatic	R lower arm	16	Movement, hot	Electric discharge, pressure	Yes/Yes	Anodal/sham
6	52/M	Cancer	L upper arm	7	Tingling, cold	Electric discharge, squeezing	No/No	Sham/anodal
7	44/M	Traumatic	R lower arm	18	Movement, itching, hot	Electric discharge, pressure	Yes/No	Anodal/sham
8	43/M	Traumatic	R upper arm	14	Movement, itching, hot	Pressure, squeezing, electrical shock	No/No	Sham/anodal
9	40/F	Traumatic	L lower arm	13	Itching, hot or cold	Electric discharge, squeezing	Yes/No	Sham/anodal
10	55/M	Vascular	L lower arm	15	Movement, itching, tingling,	Electric discharge, pressure	No/No	Anodal/sham
11	24/F	Traumatic	L lower arm	10	Movement, hot	Electric discharge, squeezing, pressure	Yes/No	Anodal/sham
12	35/F	Traumatic	L lower arm	22	Movement, hot or cold	Squeezing, pressure	Yes/No	Sham/anodal
13	58/M	Vascular	L upper arm	10	Movement, tingling, hot or cold	Electric discharge, squeezing, pressure	No/No	Sham/anodal
14	36/F	Traumatic	L lower arm	9	Movement, tingling,	Pressure, squeezing, electrical shock	Yes/No	Anodal/sham

Laser-Evoked Potentials

A solid-state laser was used (neodymium: yttrium–aluminum–perovskite (Nd: YAP); wavelength 1.04 mm, pulse duration 2–20 ms, maximum energy 7 J; Stimul 1340VR, Electronical Engineering®, Florence, Italy). The laser beam was transmitted from the generator to the stimulating probe via a 10-m length optical fiber; signals were amplified, band pass filtered (0.1–200 Hz, time analysis 1000 ms) and fed to a computer for analysis [31–33].

The stump was stimulated by laser pulses (individual variability, 15.75–24.91 J/cm²) with short duration (5 ms) and small diameter spots (5 mm), inducing pinprick sensations [26]. Twenty stimuli, whose intensity was established on the basis of the perceptible threshold of each patient, were delivered: we used a fixed intensity set at two times the individual sensory threshold, defined as the lower stimulus intensity that elicited a distinct painful pinprick sensation. In order to reduce both skin lesions and fatigue of peripheral nociceptors, the laser beam was shifted slightly by ~10 mm in a random direction between consecutive pulses [31]. Patients were reclined on a couch, wore protective goggles, and were instructed to keep their eyes open and gaze slightly downwards; they were requested to mentally count the

number of stimuli to keep their attention level constant. The interstimulus interval varied randomly between 15 and 30 s.

The main A δ -LEP complex, N2/P2, and the earlier lateralized N1 component were recorded through standard disc, non-polarizable Ag/AgCl surface electrodes (diameter 10 mm; BiomedVR, Florence, Italy). N2 and P2 components were recorded from the vertex (Cz), referenced to the earlobes; the N1 component was recorded from the contralateral temporal leads (T3 or T4), referenced to Fz [33]. The baseline-to-peak and the peak-to-peak amplitudes of N1 and N2/P2 components, respectively, were evaluated. Blinks and saccades were recorded with an EOG electrode placed on the superolateral right canthus connected to the system reference. Ground was placed on the mid-forehead.

Skin impedance was kept below 5 k Ω . An automatic artifact rejection system excluded all trials contaminated by transient signals exceeding the average value by $\pm 65 \mu\text{V}$ on each recording channel, including the EOG.

Cerebellar Transcutaneous Direct Current Stimulation

Cerebellar transcutaneous direct current stimulation (ctDCS) was applied using a battery-driven constant current stimulator

(HDCStim, Newronika®, Italy) and a pair of electrode in two saline-soaked synthetic sponges with a surface area of 35 cm². Direct current was transcranially applied for 20 min with an intensity of 2.0 mA and constant current flow was measured by an ampere meter (current density ~0.08 mA/cm²). These values are in line with those reported for cerebellar stimulation [34, 35] and are considered to be safe [36, 37]. Direct current stimulation strength remained below the sensory threshold throughout the experimental session. At the offset of tDCS, the current was decreased in a ramp-like manner, a method shown to achieve a high level of blinding between sessions [38, 39]. For anodal ctDCS, the anode was applied on the median line, 2 cm below theinion, with lateral borders about 1 cm medially to the mastoid apophysis, and the cathode over the right shoulder [21, 34, 35, 40]. For sham ctDCS, the current was turned on for 5 s and then turned off in a ramp-shaped fashion, thus inducing skin sensations similar to those produced by real ctDCS.

We stimulated the cerebellum bilaterally, as previous studies have shown that varying the position of the active electrode with ~1 cm induced negligible changes in the electrical field distribution [41, 42].

Patients were blinded to the tDCS protocol and did not discriminate between anodal and sham condition. In order to report possible adverse effects, the questionnaire developed by Brunoni and colleagues was administered to each patient [43].

Statistical Analysis

Parametric analyses were used, as all datasets successfully passed the Shapiro-Wilk test for normality ($p > 0.05$). In order to verify the absence of biases due to intra-subject changes across ctDCS sessions, a *t* test was run to compare baseline data for anodal and sham ctDCS.

A two-way repeated measures (RM) ANOVA was performed, with “stimulation” (two levels: sham and anodal) and “time” (four levels: T₀, T₁, T₂, and T₃) as experimental factors; the Bonferroni *t* test was used for multiple post hoc comparisons, with a level of significance set at $\alpha = 0.025$. Pearson’s correlation coefficient was used to compare possible changes in electrophysiological parameters with the clinical outcome.

Data were analyzed using SPSS v. 21.0 for Windows (SPSS Inc.).

Results

Laser-Evoked Potentials

The baseline laser-evoked potential (LEP) amplitudes did not change among different experimental sessions ($p > 0.3$ for all the comparisons made).

Patients showed a remarkable reduction of N1 and N2/P2 amplitudes following the anodal stimulation compared to the sham condition (N1: $F_{(3, 39)} = 10.9$, $p < 0.0001$; N2/P2: $F_{(3, 39)} = 9.6$, $p < 0.0001$, two-way ANOVA, with “stimulation” and “time” as experimental factors; N1: $p < 0.0001$; N2/P2: $p = 0.0001$, with “stimulation” as factor; Table 2). This reduction was significant at all time points, both for N1 (T₁, $p < 0.0001$; T₂, $p < 0.0001$; T₃, $p < 0.0001$) and N2/P2 responses (T₁, $p < 0.0001$; T₂, $p < 0.0001$; T₃, $p = 0.0002$, Bonferroni post hoc *t* test; Fig. 1 and Supplementary Table 1).

Clinical Assessment

The baseline VAS scores did not change among different experimental sessions ($p > 0.2$).

Patients showed a marked improvement in paroxysmal pain, with changes lasting up to 4 weeks after ctDCS completion ($F_{(3, 39)} = 14.9$, $p < 0.0001$, two-way ANOVA, with “time” and “stimulation” as experimental factors; $p < 0.0001$, with “stimulation” as factor); this improvement was significant at T₁, T₂, and T₃ when compared to the sham group ($p < 0.0001$, Bonferroni post hoc *t* test: Table 3 and Fig. 2). No difference was found both in phantom and stump pain scores, although the anodal group showed a tendency towards the improvement in phantom pain score (phantom limb pain: $F_{(3, 39)} = 2.3$, $p = 0.09$; stump pain: $F_{(3, 39)} = 1.4$, $p = 0.27$, two-way ANOVA, with “time” and “stimulation” as factors).

Phantom limb movements and sensations clearly improved following anodal stimulation ($F_{(3, 39)} = 5.3$, $p =$

Table 2 Laser-evoked potentials (LEPs). Amplitudes of N1 and N2/P2 components at baseline and their changes over time, following either the anodal or sham ctDCS. Values are expressed in mV, as mean values ± standard deviation (S.D.)

	Anodal ctDCS				Sham ctDCS			
	T ₀	T ₁	T ₂	T ₃	T ₀	T ₁	T ₂	T ₃
N1	6.2 ± 2.2	4.1 ± 2.1	4.3 ± 1.8	4.6 ± 1.7	6.7 ± 2.1	6.4 ± 2.3	6.3 ± 2.4	6.7 ± 2.0
N2/P2	11.5 ± 4.0	8.0 ± 3.1	8.4 ± 3.0	8.9 ± 3.5	11.3 ± 3.8	11.1 ± 3.9	10.9 ± 4.4	11.2 ± 3.8




Fig. 1 LEP changes. **a** Exemplificative LEPs recorded at baseline (T_0), immediately after (T_1), at 1 week (T_2), and 3 weeks (T_3) following the completion of anodal ctDCS. Note the reduction of LEP amplitudes over time both for N1 and N2/P2 components. **b** Changes in LEP amplitudes between the anodal (black circles) and sham condition (white squares).

Data are given as percentage of baseline value \pm S.D. At each time interval, the statistical significance refers to the comparison between anodal (active) and sham (placebo) stimulation (***) $p < 0.001$, Bonferroni post hoc comparison)

0.004; $F_{(3, 39)} = 8.7$, $p = 0.0002$, respectively, two-way ANOVA, with “time” and “stimulation” as experimental factors), and the reduction in VAS scores was significant at all time intervals when compared to the sham condition (Fig. 3 and Supplementary Table 1).

Changes in paroxysmal pain VAS scores linearly correlated with the reduction in LEP amplitudes. Indeed, patients with greater clinical improvement showed a more robust modulation of evoked responses ($p = 0.0004$, Pearson’s correlation coefficient).

Discussion

Anodal ctDCS improves both paroxysmal pain and non-painful phantom limb sensations in subjects with upper limb amputations.

Previous studies have shown that tDCS applied over the motor cortex (M1) is a promising therapeutic tool in PLP, with effects likely arising from a transient restoration of the cortical representation of the phantom limb [29, 30, 44]; although the exact mechanisms of action are still

Table 3 Clinical assessment. VAS scores both for painful and non-painful phantom sensations, following either the anodal or sham ctDCS. Values are expressed as mean values \pm standard deviation (S.D.)

	Anodal ctDCS				Sham ctDCS			
	T_0	T_1	T_2	T_3	T_0	T_1	T_2	T_3
Phantom limb pain	6.6 \pm 2.0	5.6 \pm 2.1	5.9 \pm 2.1	5.5 \pm 2.2	6.5 \pm 2.3	5.9 \pm 2.4	6.1 \pm 1.8	6.4 \pm 2.4
Paroxysmal pain	7.8 \pm 1.8	4.6 \pm 2.0	4.5 \pm 1.8	4.2 \pm 2.1	7.9 \pm 1.7	7.5 \pm 1.5	7.7 \pm 1.7	7.4 \pm 1.6
Stump (residual) pain	6.4 \pm 2.2	5.3 \pm 1.9	5.5 \pm 2.0	4.4 \pm 2.2	6.5 \pm 2.3	5.9 \pm 2.0	6.1 \pm 2.3	6.0 \pm 2.2
Phantom movements	6.9 \pm 2.0	4.5 \pm 2.3	4.6 \pm 1.9	3.9 \pm 1.9	6.9 \pm 2.0	6.1 \pm 2.3	6.2 \pm 2.5	5.9 \pm 2.3
Phantom sensations	9.2 \pm 1.0	6.0 \pm 2.7	5.4 \pm 2.2	5.4 \pm 2.0	9.5 \pm 0.8	8.6 \pm 1.0	8.6 \pm 1.1	8.4 \pm 1.0




Fig. 2 Painful phantom limb phenomena. Changes in VAS scores over time (paroxysmal pain, phantom limb pain, and stump pain); note that anodal ctDCS (black circles) significantly improved paroxysmal pain compared to the sham condition (white squares). Data are reported as

percentage of baseline value \pm S.D. At each time interval, the statistical significance refers to the comparison between anodal (active) and sham (placebo) stimulation ($***p < 0.001$, Bonferroni post hoc)

debated, this reinforcement seems to play a role in PLP relief and behavioral therapies targeting motor representation have shown encouraging results [45, 46]. Also, high-frequency repetitive transcranial magnetic stimulation (rTMS) on the contralateral primary motor cortex was shown to improve PLP in land mine victims [47], although other studies reported conflicting results about the use of rTMS, either low or high frequency, in amputated patients [48–50].

Here, the reduction in N1 and N2/P2 amplitudes confirms data in healthy humans [21, 24] and suggests that anodal ctDCS is able to modulate both somatosensory and cingulate cortices, interfering with the sensory-discriminative and emotional dimensions of pain [25, 51].

Interestingly, our results proved ctDCS effects on painful and non-painful phantom limb phenomena, in accordance with previous papers supporting a cerebellar involvement in phantom limb sensations [52–54]. Others studies found a clinical dissociation between painful and non-painful phantom phenomena following tDCS applied over M1 [29]. The discrepancy between these results and our findings is probably due to different tDCS target, with anodal ctDCS leading to a sustained cerebellar-brain inhibition (CBI), not restricted to motor areas. Further support comes from a recent paper showing that PLP relief

significantly correlated with reduced activity in both primary somatosensory and motor cortices (S1/M1): the authors proved that anodal tDCS applied over the S1/M1 missing hand cortex leads to PLP relief, longer than that induced by M1 stimulation alone, probably by restoring defective intracortical inhibitory processes [55].

Accordingly, an increased activity within S1/M1 areas has been recently recognized as a marker of chronic PLP [14, 15] and transcranial magnetic stimulation (TMS) studies have shown that motor thresholds and intracortical inhibition decrease for the muscle proximal to the amputation [56, 57]; although the relationship between increased motor excitability and PLP remains unclear, these changes are greater in amputees with PLP than in pain-free patients and positively correlated with the severity of pain [10].

As an alternative, not mutually exclusive explanation, we cannot rule out the possibility of a modulation of the lemniscal pathways, as suggested by the selective modulation of paroxysmal pain scores. Some studies have proposed that pain paroxysms are due to demyelination of non-nociceptive A-beta fibers, whereas spontaneous constant pain arises from damage to nociceptive A-delta afferents [58, 59]. That may explain, at least in part, the lack of changes in PLP scores. Accordingly,




Fig. 3 Non-painful phantom limb phenomena. Changes in VAS scores; note that anodal ctDCS (black circles) remarkably reduced both phantom movements and sensations compared to the sham condition (white squares). Data are given as percentage of baseline value \pm S.D. At each

time interval, the statistical significance refers to the comparison between anodal (active) and sham (placebo) stimulation ($**p < 0.01$; $***p < 0.001$, Bonferroni post hoc)

ctDCS may act not only on cortical networks but also on spinal neurons, influencing pain processing through top-down and bottom-up mechanisms [60].

Finally, the lack of changes in stump pain is not surprising, as it refers to the so-called residual limb pain (RLP), localized to the remaining body part after amputation and likely due to peripheral factors, comprising post-surgical neuromas and nociceptor sensitization, difficult to treat with non-invasive brain stimulation techniques [3, 61, 62].

Limitations of the Study

Our study has some limitations. First, only patients with upper limb amputations were enrolled; our sample included a large number of young patients, whose amputations mainly resulted from traumatic injuries. These patients do not usually undergo preoperative peripheral nerve block, a method shown to reduce the occurrence of PLP [63], in accordance with the hypothesis that phantom pain is primed by nociceptive input before the amputation [12, 13]. It would be of interest to complete the trial including patients with lower limb amputation.

Second, an extensive neurophysiological evaluation of peripheral nerves and sympathetic function has not been included. It may be useful for the study of mechanisms underlying phantom limb pain, residual phantom pain, and non-painful sensations.

Third, no patient underwent mirror therapy (MT); MT may enhance the effects of anodal ctDCS, as described for the stimulation of primary motor cortex [44].

Conclusions

To our knowledge, this is the first study describing analgesic effects of cerebellar direct current stimulation in neuropathic pain and the first extensively assessing LEP changes in amputees. Cerebellar tDCS improved painful and non-painful sensations, through different mechanisms of action, providing a novel therapeutic option for the treatment of PLP. Further studies are needed to improve this technique, possibly in association with behavioral strategies. Finally, ctDCS may be also used to reduce the pre-amputation pain before surgery, in order to prevent central and spinal sensitization that plays a critical role, especially for amputations due to vascular or neoplastic causes, where surgery may be planned weeks before, possibly avoiding maladaptive cortical changes priming pain before the amputation.

Acknowledgments We gratefully acknowledge the participation of all subjects, as well as Mr. C. Orsini and Mr. D. Barloscio for their excellent technical assistance. The paper was supported in part by the Italian operating and development MIUR PRIN grant year 2006, n.2006062332_002.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

- Alviar MJ, Hale T, Dunga M. Pharmacologic interventions for treating phantom limb pain. *Cochrane Database Syst Rev*. 2016;10:CD006380.
- Flor H. Phantom-limb pain: characteristics, causes, and treatment. *Lancet Neurol*. 2002;1(3):182–9.
- Kooijman CM, Dijkstra PU, Geertzen JH, Elzinga A, van der Schans CP. Phantom pain and phantom sensations in upper limb amputees: an epidemiological study. *Pain*. 2000;87(1):33–41.
- Keil G. So-called initial description of phantom pain by Ambroise pare. “chose digne d’admiration et quasi incroyable”: the “douleurs parties mortes et amputees”. *Fortschr Med*. 1990;108(4):62–6.
- Diers M, Kamping S, Kirsch P, Rance M, Bekrater-Bodmann R, Foell J, et al. Illusion-related brain activations: a new virtual reality mirror box system for use during functional magnetic resonance imaging. *Brain Res*. 2015;1594:173–82.
- Diers M, Christmann C, Koeppel C, Ruf M, Flor H. Mirrored, imagined and executed movements differentially activate sensorimotor cortex in amputees with and without phantom limb pain. *Pain*. 2010;149(2):296–304.
- Flor H, Nikolajsen L, Staehelin JT. Phantom limb pain: a case of maladaptive CNS plasticity? *Nat Rev Neurosci*. 2006;7(11):873–81.
- Lotze M, Flor H, Grodd W, Larbig W, Birbaumer N. Phantom movements and pain. An fMRI study in upper limb amputees. *Brain*. 2001;124(Pt 11):2268–77.
- Suzuki R, Dickenson A. Spinal and supraspinal contributions to central sensitization in peripheral neuropathy. *Neurosignals*. 2005;14(4):175–81.
- Karl A, Birbaumer N, Lutzenberger W, Cohen LG, Flor H. Reorganization of motor and somatosensory cortex in upper extremity amputees with phantom limb pain. *J Neurosci*. 2001;21(10):3609–18.
- Wrigley PJ, Press SR, Gustin SM, Macefield VG, Gandevia SC, Cousins MJ, et al. Neuropathic pain and primary somatosensory cortex reorganization following spinal cord injury. *Pain*. 2009;141(1–2):52–9.
- Raffin E, Richard N, Giroux P, Reilly KT. Primary motor cortex changes after amputation correlate with phantom limb pain and the ability to move the phantom limb. *Neuroimage*. 2016;130:134–44.
- Andoh J, Milde C, Tsao JW, Flor H. Cortical plasticity as a basis of phantom limb pain: fact or fiction? *Neuroscience*. 2018;387:85–91.
- Kikkert S, Johansen-Berg H, Tracey I, Makin TR. Reaffirming the link between chronic phantom limb pain and maintained missing hand representation. *Cortex*. 2018;106:174–84.
- Makin TR, Scholz J, Filippini N, Henderson Slater D, Tracey I, Johansen-Berg H. Phantom pain is associated with preserved structure and function in the former hand area. *Nat Commun*. 2013;4:1570.

16. Ferraro F, Jacopetti M, Spallone V, Padua L, Traballesi M, Brunelli S, et al. Diagnosis and treatment of pain in plexopathy, radiculopathy, peripheral neuropathy and phantom limb pain. Evidence and recommendations from the Italian consensus conference on pain on Neurorehabilitation. *Eur J Phys Rehabil Med*. 2016;52(6):855–66.
17. McAuley J, van Groningen R, Green C. Spinal cord stimulation for intractable pain following limb amputation. *Neuromodulation*. 2013;16(6):530–6 discussion 6.
18. Aiyer R, Barkin RL, Bhatia A, Gungor S. A systematic review on the treatment of phantom limb pain with spinal cord stimulation. *Pain Manag*. 2017;7(1):59–69.
19. Borsook D, Moulton EA, Tully S, Schmahmann JD, Becerra L. Human cerebellar responses to brush and heat stimuli in healthy and neuropathic pain subjects. *Cerebellum*. 2008;7(3):252–72.
20. Duerden EG, Albanese MC. Localization of pain-related brain activation: a meta-analysis of neuroimaging data. *Hum Brain Mapp*. 2013;34(1):109–49.
21. Bocci T, Santarcangelo E, Vannini B, Torzini A, Carli G, Ferrucci R, et al. Cerebellar direct current stimulation modulates pain perception in humans. *Restor Neurol Neurosci*. 2015;33(5):597–609.
22. Bocci T, Barloscio D, Parenti L, Sartucci F, Carli G, Santarcangelo EL. High hypnotizability impairs the cerebellar control of pain. *Cerebellum*. 2017;16(1):55–61.
23. Baarbe JK, Yelder P, Haavik H, Holmes MWR, Murphy BA. Subclinical recurrent neck pain and its treatment impacts motor training-induced plasticity of the cerebellum and motor cortex. *PLoS One*. 2018;13(2):e0193413.
24. Pereira M, Rafiq B, Chowdhury E, Babayev J, Boo H, Metwaly R, et al. Anodal cerebellar tDCS modulates lower extremity pain perception. *NeuroRehabilitation*. 2017;40(2):195–200.
25. Valeriani M, Le Pera D, Restuccia D, de Armas L, Miliucci R, Betti V, et al. Parallel spinal pathways generate the middle-latency N1 and the late P2 components of the laser evoked potentials. *Clin Neurophysiol*. 2007;118(5):1097–104.
26. Valeriani M, Pazzaglia C, Cruccu G, Truini A. Clinical usefulness of laser evoked potentials. *Neurophysiol Clin*. 2012;42(5):345–53.
27. Garcia-Larrea L, Frot M, Valeriani M. Brain generators of laser-evoked potentials: from dipoles to functional significance. *Neurophysiol Clin*. 2003;33(6):279–92.
28. Vogt BA, Derbyshire S, Jones AK. Pain processing in four regions of human cingulate cortex localized with co-registered PET and MR imaging. *Eur J Neurosci*. 1996;8(7):1461–73.
29. Bolognini N, Olgiati E, Maravita A, Ferraro F, Fregni F. Motor and parietal cortex stimulation for phantom limb pain and sensations. *Pain*. 2013;154(8):1274–80.
30. Bolognini N, Spandri V, Ferraro F, Salmaggi A, Molinari AC, Fregni F, et al. Immediate and sustained effects of 5-day transcranial direct current stimulation of the motor cortex in phantom limb pain. *J Pain*. 2015;16(7):657–65.
31. Truini A, Galeotti F, Romaniello A, Virtuoso M, Iannetti GD, Cruccu G. Laser-evoked potentials: normative values. *Clin Neurophysiol*. 2005;116(4):821–6.
32. Truini A, Panuccio G, Galeotti F, Maluccio MR, Sartucci F, Avoli M, et al. Laser-evoked potentials as a tool for assessing the efficacy of antinociceptive drugs. *Eur J Pain*. 2010;14(2):222–5.
33. Cruccu G, Aminoff MJ, Curio G, Guerit JM, Kakigi R, Manguiere F, et al. Recommendations for the clinical use of somatosensory-evoked potentials. *Clin Neurophysiol*. 2008;119(8):1705–19.
34. Ferrucci R, Marceglia S, Vergari M, Cogiamanian F, Mrakic-Sposta S, Mameli F, et al. Cerebellar transcranial direct current stimulation impairs the practice-dependent proficiency increase in working memory. *J Cogn Neurosci*. 2008;20(9):1687–97.
35. Ferrucci R, Brunoni AR, Parazzini M, Vergari M, Rossi E, Fumagalli M, et al. Modulating human procedural learning by cerebellar transcranial direct current stimulation. *Cerebellum*. 2013;12(4):485–92.
36. Iyer MB, Mattu U, Grafman J, Lomarev M, Sato S, Wassermann EM. Safety and cognitive effect of frontal DC brain polarization in healthy individuals. *Neurology*. 2005;64(5):872–5.
37. Nitsche MA, Liebetanz D, Lang N, Antal A, Tergau F, Paulus W. Safety criteria for transcranial direct current stimulation (tDCS) in humans. *Clin Neurophysiol*. 2003;114(11):2220–2 author reply 2–3.
38. Gandiga PC, Hummel FC, Cohen LG. Transcranial DC stimulation (tDCS): a tool for double-blind sham-controlled clinical studies in brain stimulation. *Clin Neurophysiol*. 2006;117(4):845–50.
39. Galea JM, Jayaram G, Ajagbe L, Celnik P. Modulation of cerebellar excitability by polarity-specific noninvasive direct current stimulation. *J Neurosci*. 2009;29(28):9115–22.
40. Bocci T, Ferrucci R, Barloscio D, Parenti L, Cortese F, Priori A, et al. Cerebellar direct current stimulation modulates hand blink reflex: implications for defensive behavior in humans. *Physiol Rep*. 2018;6(10):e13471.
41. Parazzini M, Rossi E, Ferrucci R, Liomi I, Priori A, Ravazzani P. Modelling the electric field and the current density generated by cerebellar transcranial DC stimulation in humans. *Clin Neurophysiol*. 2014;125(3):577–84.
42. Parazzini M, Rossi E, Ferrucci R, Fiocchi S, Liomi I, Priori A, et al. Computational model of cerebellar transcranial direct current stimulation. *Conf Proc IEEE Eng Med Biol Soc*. 2013;2013:237–40.
43. Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. *Int J Neuropsychopharmacol*. 2011;14(8):1133–45.
44. Pinto CB, Saleh Velez FG, Bolognini N, Crandell D, Merabet LB, Fregni F. Optimizing rehabilitation for phantom limb pain using mirror therapy and transcranial direct current stimulation: a randomized, double-blind clinical trial study protocol. *JMIR Res Protoc*. 2016;5(3):e138.
45. Moseley GL, Flor H. Targeting cortical representations in the treatment of chronic pain: a review. *Neurorehabil Neural Repair*. 2012;26(6):646–52.
46. MacIver K, Lloyd DM, Kelly S, Roberts N, Nummikko T. Phantom limb pain, cortical reorganization and the therapeutic effect of mental imagery. *Brain*. 2008;131(Pt 8):2181–91.
47. Malavera A, Silva FA, Fregni F, Carrillo S, Garcia RG. Repetitive transcranial magnetic stimulation for phantom limb pain in land mine victims: a double-blinded, randomized, sham-controlled trial. *J Pain*. 2016;17(8):911–8.
48. Topper R, Foltys H, Meister IG, Sparing R, Borojerd B. Repetitive transcranial magnetic stimulation of the parietal cortex transiently ameliorates phantom limb pain-like syndrome. *Clin Neurophysiol*. 2003;114(8):1521–30.
49. Ahmed MA, Mohamed SA, Sayed D. Long-term antalgic effects of repetitive transcranial magnetic stimulation of motor cortex and serum beta-endorphin in patients with phantom pain. *Neurol Res*. 2011;33(9):953–8.
50. Lee JH, Byun JH, Choe YR, Lim SK, Lee KY, Choi IS. Successful treatment of phantom limb pain by 1 Hz repetitive transcranial magnetic stimulation over affected supplementary motor complex: a case report. *Ann Rehabil Med*. 2015;39(4):630–3.
51. Garcia-Larrea L, Peyron R, Laurent B, Manguiere F. Association and dissociation between laser-evoked potentials and pain perception. *Neuroreport*. 1997;8(17):3785–9.
52. Rosen G, Hugdahl K, Erslund L, Lundervold A, Smievoll AI, Barndon R, et al. Different brain areas activated during imagery of painful and non-painful ‘finger movements’ in a subject with an amputated arm. *Neurocase*. 2001;7(3):255–60.
53. Anderson WS, Lenz FA. Review of motor and phantom-related imagery. *Neuroreport*. 2011;22(17):939–42.

54. Raffin E, Mattout J, Reilly KT, Giroux P. Disentangling motor execution from motor imagery with the phantom limb. *Brain*. 2012;135(Pt 2):582–95.
55. Kikkert S, Mezue M, O'Shea J, Henderson Slater D, Johansen-Berg H, Tracey I, et al. Neural basis of induced phantom limb pain relief. *Ann Neurol*. 2019;85(1):59–73.
56. Cohen LG, Bandinelli S, Findley TW, Hallett M. Motor reorganization after upper limb amputation in man. A study with focal magnetic stimulation. *Brain*. 1991;114(Pt 1B):615–27.
57. Dettmers C, Adler T, Rzanny R, van Schayck R, Gaser C, Weiss T, et al. Increased excitability in the primary motor cortex and supplementary motor area in patients with phantom limb pain after upper limb amputation. *Neurosci Lett*. 2001;307(2):109–12.
58. Truini A, Galeotti F, Haanpaa M, Zucchi R, Albanesi A, Biasiotta A, et al. Pathophysiology of pain in postherpetic neuralgia: a clinical and neurophysiological study. *Pain*. 2008;140(3):405–10.
59. Truini A, Padua L, Biasiotta A, Caliendo P, Pazzaglia C, Galeotti F, et al. Differential involvement of A-delta and A-beta fibres in neuropathic pain related to carpal tunnel syndrome. *Pain*. 2009;145(1–2):105–9.
60. Singer T, Seymour B, O'Doherty J, Kaube H, Dolan RJ, Frith CD. Empathy for pain involves the affective but not sensory components of pain. *Science*. 2004;303(5661):1157–62.
61. Ehde DM, Czerniecki JM, Smith DG, Campbell KM, Edwards WT, Jensen MP, et al. Chronic phantom sensations, phantom pain, residual limb pain, and other regional pain after lower limb amputation. *Arch Phys Med Rehabil*. 2000;81(8):1039–44.
62. Hunter JP, Katz J, Davis KD. Dissociation of phantom limb phenomena from stump tactile spatial acuity and sensory thresholds. *Brain*. 2005;128(Pt 2):308–20.
63. Becotte A, de Medicis E, Lapie V, Martin R, Gagnon V. Preoperative continuous sciatic nerve block for perioperative analgesia and for phantom limb prevention. *J Clin Anesth*. 2012;24(3):256–7.